{"": [92, 1576, 0], "Introduction": [1577, 4626, 0], "Clinical data support nAb as a biomarker of protection": [4627, 7859, 0], "RBD is a key target of nAb": [7860, 9032, 0], "RBD is a key target for potent cross-neutralizing monoclonal antibodies": [9033, 12592, 0], "NTD: a functional neutralization target": [12593, 13711, 0], "RBD may be undergoing convergent evolution": [13712, 16137, 0], "RBD-specific memory B cells": [16138, 17353, 0], "CD4+ and CD8+ T-cell immune responses to RBD": [17354, 21973, 0], "Preclinical studies support RBD as a potent vaccine antigen": [21974, 23185, 0], "Prototype RBD-np vaccine": [23186, 28913, 0], "RBD-based vaccines in the clinic": [28914, 32585, 0], "Conclusions": [32586, 34302, 0]}